Background Calcineurin inhibitors post renal transplantation are recognised to
INTRODUCTION
Tubulopathy, in the form of hyperkalaemia, metabolic acidosis and salt-wasting syndromes, has been recognised in the literature, post transplantation 1, 2 . However, the incidence of this type 4 renal tubular acidosis remains unknown. Whilst tubular dysfunction can occur secondary to renal impairment and interstitial damage from acute episodes and nephrotoxic drugs 3 ; immunosuppressive regimens, namely calcineurin inhibitors (CNI) (Ciclosporin, Tacrolimus) have also been directly implicated 4, 5, 6 . These drugs are thought to lead to a down regulation of the mineralocorticoid receptors and a resultant pseudohypoaldosteronism picture with normal aldosterone levels. There is perhaps a suggestion that tubulopathy is more associated with tacrolimus than ciclosporin 5 with transplant immunosuppressive regimens now more likely to use the former.
Fludrocortisone, a corticosteroid with high glucocorticoid and potent mineralocorticoid activity, has been shown to be beneficial when used in adults with end-stage renal disease (ESRD) who are anuric, on haemodialysis and hyperkalaemic 7 . In managing CNI associated hyperkalaemia, adult literature reports a small number of cases with a beneficial response to fludrocortisone, and emphasises the benefits of fludrocortisone as a safe and effective treatment in reversing post transplant tubulopathies with normalisation of electrolytes 8, 9, 10 .
Tubulopathy when occurring post transplantation requires the initiation of electrolyte supplementation, particularly sodium bicarbonate and sodium chloride replacement, to aid amongst other factors, growth. However, this adds to the medication burden, potentially therefore affecting compliance 11 .
Paediatric data remains limited with only one centre reporting the efficacy of fludrocortisone in a paediatric population for management of tubulopathy post renal transplantation 12 . We report our national experience of the efficacy of fludrocortisone 5 in the management of post renal transplant tubulopathy and its potential benefits in paediatric renal transplantation.
MATERIALS AND METHODS
A retrospective case review of data collected from a multi-centre, electronic renal patient database ( Ethics approval was not required as this was a retrospective case-series corresponding to service audit.
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RESULTS
Clinical and demographic data
Forty-seven (35 males and 12 females) paediatric renal transplant recipients were identified from the SERPR database and reviewed in the tertiary paediatric renal service during the study period. 23 (17 males) patients (48.9%) were commenced on sodium supplementation (sodium chloride, sodium bicarbonate). Of the cohort of patients commenced on sodium supplementation, 6 were also commenced on fludrocortisone. A further 3 patients were commenced directly onto fludrocortisone to directly manage tubular dysfunction post transplantation. A total of 9 patients received fludrocortisone ( Table 1 ). Two of the 3 patients commenced directly onto fludrocortisone had previously been on sodium supplementation but not during the study period. 
Effect on sodium supplementation
At follow-up, all patients commenced on fludrocortisone therapy were able to discontinue sodium bicarbonate supplementation and either had a reduction or no increase in the total daily dose of sodium chloride ( (Fig. 1a) .
Serum potassium levels (Fig. 1b) were significantly lower following treatment with fludrocortisone, 5.2 compared to 4.5 mmol/l, p=0.04. Two patients had received specific dietetic advice on maintaining a low potassium diet prior to commencing fludrocortisone. One patient in this cohort had a strict potassium restricted diet; this patient was not on electrolyte supplementation prior to treatment with fludrocortisone.
There was no significant effect on blood pressure following treatment with fludrocortisone, systolic BP 107 compared to 106 mmHg, p=0.81; diastolic BP 68 compared to 66 mmHg, p= 0.37. In addition, there was no significant difference in median systolic blood pressure z-scores (based on age, height and gender) before and whilst on fludrocortisone, 0.99 vs 0.85, p= 0.92 (Fig. 1c) . Three patients were taking amlodipine as an antihypertensive agent prior to commencing fludrocortisone.
Of these, one patient had commenced amlodipine one month prior to fludrocortisone and two patients had started amlodipine one year prior to treatment with fludrocortisone. All patients' antihypertensive doses remained unchanged at followup.
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There were no side effects of treatment with fludrocortisone reported in this cohort, requiring cessation of therapy. Due to the large range of tacrolimus levels and small numbers in our cohort, we were unable to determine whether tubular CNI related adverse effects were dose related. However, our study noted a reduction in electrolyte supplementation, a reduction in serum potassium levels with no change in renal function and no change in blood pressure at follow-up. The hypokalaemic properties of fludrocortisone are an added benefit as patients on a potassium restricted diet were able to liberalise their dietary potassium intake. Our study has demonstrated that fludrocortisone is well tolerated, with no side effects occurring secondary to treatment in our cohort. The insignificant differences in eGFR and blood pressure are unlikely to be due to the short interval as some patients were followed up for up to 20 months. However, a longer period of follow-up would be ideal and on going follow-up is still required to monitor for long-term side Patients 1-6 were taking sodium supplements prior to commencing fludrocortisone.
DISCUSSION
Patients 7-9 were commenced directly onto fludrocortisone. 
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